MiRNA-3978 regulates peritoneal gastric cancer metastasis by targeting legumain
Metrics: PDF 1668 views | HTML 1905 views | ?
Yi Zhang1, Yuan-yu Wu1, Jun-nan Jiang1, Xue-song Liu1, Fu-jian Ji1, Xue-dong Fang1
1Department of General Surgery, China-Japan Union Hospital, Jilin University, Changchun, Jilin 130012, China
Xue-dong Fang, email: [email protected]
Fu-jian Ji, email: [email protected]
Keywords: gastric cancer, miRNA-3978, legumain, metastasis
Received: July 06, 2016 Accepted: September 21, 2016 Published: October 26, 2016
Gastric cancer incidence and mortality are among the highest in China, with majority of the mortality related to peritoneal metastasis of gastric cancer. Treatment is limited to radical resection, which is impeded by incidence of metastasis at time of initial diagnosis, thus making it imperative to identify diagnostic and prognostic biomarkers. Legumain, a lysosomal cysteine endopeptidase of the asparaginyl endopeptidase family, has been shown to be overexpressed in patients with metastatic gastric cancer disease and its expression was positively correlated to both disease progression and outcome. However, the mechanism of legumain expression is currently unknown. Legumain overexpression was found to occur at the level of post transcriptional gene regulation. In situ prediction algorithms identified legumain as a putative target of miR-3978. MiR-3978 was significantly decreased in peritoneal metastatic tissue specimens and in MKN45 cells that mimic peritoneal metastasis features. Reporter assays using LGMN (encoding legumain) 3’ untranslated region (UTR) showed that miR-3978 interacted with the wild-type but not miR-3978-seed mutant. Ectopic expression of miR-3978 mimic in the MKN45 cell line significantly decreased proliferation and suppressed in vitro migration and invasion. The miR-3978 mimic inhibited gastric carcinoma and metastatic progression in a mice model by regulating legumain protein expression. Inverse correlation of LGMN mRNA and miR-3978 levels in 20 gastric patients at different stages of metastatic disease confirmed the same. Cumulatively, our results indicate that loss of miR-3978 leads to increased expression of legumain, which indicates that miR-3978might be a biomarker for peritoneal metastasis in patients with gastric cancer.
The Republic of China has one of the highest incidences of gastric cancer globally, with 300,000 patients with gastric cancer projected to die annually . Even though the treatment of choice in gastric cancer is radical resection, 50% of the patients develop peritoneal metastasis [2–7] The major limitation in treating gastric cancer patients with peritoneal metastasis is lack of molecular markers that would lead to early diagnosis, in turn increasing the efficacy of radical resection as a treatment modality, and lack of mechanistic understanding of the processes that drives peritoneal metastasis .
It has been shown that the lysosomal cysteine endopeptidase of the asparaginyl endopeptidase family, legumain or asparaginyl endopeptidase (AEP) [9, 10], is overexpressed in patients with metastatic gastric cancer [11, 12]. It has also been shown that legumain facilitates epithelial to mesenchymal transition (EMT) and metastatic progression in gastric cancer through activation of MAPK and Akt signaling pathways and overexpressed in different cancers [13–19]. However, the precise mechanism about what induces legumain expression during metastatic progression of gastric cancer is not known, which was the objective of the present study. Our findings cumulatively indicate that the microRNA-3978 (miR-3978) regulates legumain expression in normal peritoneum. However, during gastric cancer progression miR-3978 expression is suppressed resulting in concomitant increase in legumain expression.
To explore the mechanism(s) regulating legumain expression, we first evaluated legumain expression in peritoneal metastatic samples obtained from gastric cancer patients. As shown in Figure 1A, legumain was significantly overexpressed in all patient samples tested compared to normal peritoneal wash. Since, legumain was earlier shown to aid in metastatic progression of legumain by inducing EMT (13), we assayed the samples for expression of epithelial cell marker, E-cadherin, and mesenchymal cell markers, fibronectin and vimentin. E-cadherin was detected in only one patient sample, where the mesenchymal markers were also significantly less than the other samples (Figure 1A). Overall, the patient derived samples had correlative expression of legumain and mesenchymal cell markers. To understand if the difference in legumain expression was due to differential transcription of LGMN in patients with peritoneal metastasis, we performed qRT-PCR (Figure 1B). There was no significant difference in LGMN (encoding legumain) in samples derived from patients with and without peritoneal metastasis, indicating a post-transcriptional regulation of LGMN expression.
Figure 1: Legumain is overexpressed in gastric cancer patients with peritoneal metastasis. A. Western blot analysis of legumain expression and indicated epithelial (E-cadherin) and mesenchymal cell (fibronectin and vimentin) markers in samples obtained from normal peritoneum (N) or patients with metastatic gastric cancer (P1-P7). Blots were probed with GAPDH antibody to validate equivalent loading. B. Real-time PCR analysis of LGMN (encoding legumain) expression in gastric cancer patients with and without peritoneal metastasis (NS: P>0.05).
To explore the possibility of miRNA-mediated regulation of LGMN expression, we used two independent algorithms to in situ predict the miRNAs targeting LGMN, TargetScan and microCosm (Figure 2A, and Supplementary Table S1). No conserved miRNAs were detected; however, both algorithms detected miR-1624, miR-3148, miR-3978, and miR-890 as putative poorly conserved miRNAs targeting LGMN. There was no previous knowledge available of LGMN being targeted by miRNAs, hence we decided to pursue it further.
Figure 2: Prediction of LGMN as a target of miR-3978. A. Complementary seed match between indicated miRNAs and the 3′ UTR of LGMN as predicted by TargetScan software. The full complement of predicted miRNAs are indicated in Supplementary Table S1. B. Real-time PCR analysis of indicated miRNA expression in gastric cancer patients with peritoneal metastasis (normalized to RNU6B and normal peritoneal tissue). C and D. Real-time PCR (NS: P>0.05) (C) and western blot (D) analysis of legumain expression in indicated cell lines.
We next determined expression levels of the aforementioned four miRNAs in tumor tissue specimens obtained from gastric cancer patients. As shown in Figure 2B, miR-3978 was the only miRNA that showed significantly suppressed expression in gastric cancer patients with peritoneal metastasis (P<0.05), whereas the other three were either overexpressed or did not show significant change.
To determine if LGMN is actually being targeted by miR-3978, we decided of using the well-differentiated cell line mimicking peritoneal metastasis, MKN45, and the human mesothelial cell line, HMrSV5. Even though LGMN transcript expression was comparable in these two cell lines (Figure 2C), legumain was significantly overexpressed in MKN45 cells compared to HMrSV5 (Figure 2D). In contrast, miR-2978 expression was significantly higher in the HMrSV5 cells compared to the MKN45 cells (data not shown). Hence, MKN45 and HMrSV5 provided us a good in vitro model system to further query the role of miR-3978 in regulation of legumain protein expression.
We next determined if LGMN is a bona fide target of miR-3978. To test putative interaction between the 3’UTR of LGMN and miR-3978, luciferase reporter constructs containing the wild-type LGMN 3′UTR were transfected in MKN45 and HMrSV5 cells. LGMN 3’UTR containing reporter were inhibited 3.2 ± 0.05 folds (P = 0.004) in HMrSV5 cells compared to MKN45 cells (Figure 3A). To confirm that the effects observed was due to miR-3978 targeting the LGMN 3’UTR, we generated and tested miR-3978 and miR-6124 binding mutants of the LGMN 3’UTR reporter (nucleotides 19-26 corresponding to the miR-6124 binding site, and 21-27 corresponding to miR-3978 binding site). The miR-3978 binding mutant LGMN reporter did not show any difference in relative luciferase activity between MKN45 and HMrSV5 cells (p>0.05) (Figure 3A), confirming that LGMN mRNA was being targeted by the miR-3978 in these cells. However, the miR-6124 binding mutant LGMN reporter was still being repressed in the HMrSV5 cells, indicating that LGMN is not a bona fide target of miR_6124 (Figure 3A). To further confirm that differential miR-3978, but not miR-6124, expression can modulate the expression of the LGMN reporters, the cells were co-transfected with miR-3978 or miR-6124 mimic or antagomir. Whereas miR-3978 antagomir de-repressed LGMN 3’-UTR reporter expression in HMrSV-5 cells, miR-3978 mimic abrogated reporter expression in the MKN45 cells (Figure 3B), confirming LGMN as a bona fide target of miR-3978 in these cell lines. However, neither miR-6124 antagomir nor mimic resulted in any change of LGMN reporter expression in either HMrSV5 or MKN45 cells (Figure 3B), confirming that LGMN is not a bona fide target of miR-6124.
Figure 3: LGMN is a bona-fide target of miR-3978 in gastric cancer. A. Relative luciferase activity of transiently transfected luciferase reporter constructs containing either wild-type or mutated (miR-3978 binding site deleted) LGMN 3’ UTR in MKN45 and HMrSV5 cells. B. Relative luciferase activity of transiently transfected luciferase reporter constructs containing wild-type LGMN 3’ UTR in MKN45 and HMrSV5 cells, either mock transfected or transfected with miR-3978 antagomir and mimic as indicated (NS: P>0.05; *P<0.05).
To determine whether differential miR-3978 expression affects cell proliferation, cell viability assays were carried out with MKN45 cells, mock transfected or transfected with miR-3978 mimic. Transfection with miR-3978 mimic suppressed cell proliferation after day 1 (mock vs miR-3978 mimic – 0.49 ± 0.04 vs 0.29 ± 0.05, p<0.05), day 2 (mock vs miR-3978 mimic – 0.92 ± 0.04 vs 0.43 ± 0.09, p<0.05), and day 3 (mock vs miR-3978 mimic – 2.04 ± 0.06 vs 1.04 ± 0.09, p<0.05) (Figure 4A). Our results suggested that legumain potentiates cell proliferation in metastatic gastric cancer that can be inhibited by miR-3978 expression.
Figure 4: MiR-3978 expression levels dictate cell viability, migration and invasion abilities in GBM cells. A. Cell viability was measured in MKN45 cells mock transfected or transfected with miR-3978 mimic at 24, 48, and 72 hours after transfection by the MTT assay. B and C. Modulation of miR-3978 changes cell migration and invasion abilities in the MKN45 cells. The migrated and invasive cells were photographed using a microscope (data not shown), and the number of the migrated and invasive cells in every field was counted and represented as percent of total cells at the beginning of the assay. Error bars, S.D. *P<0.05.
We then scored each of the individual transfectants MKN45 cells (mock and miR-3978 mimic), for migration (Figure 4B) and invasion (Figure 4C) in standard transwell assays. Using these criteria, phase contrast imaging (data not shown) and quantification showed that overexpression of miR-3978 inhibited in vitro migration (mock vs miR-3978 mimic – 78 ± 3 vs 49 ± 2, p<0.05) (Figure 4B), and invasion (mock vs miR-3978 mimic – 69 ± 5 vs 27 ± 4, p<0.05) (Figure 4C). Our results suggested that miR-3978 expression can inhibit in vitro migration and invasion in gastric cancer, which occurs by repression of LGMN expression. Cumulatively, the profound repression in relative expression of miR-3978 and increased expression of legumain in metastatic gastric cancer tissue or cell line along with its capacity to impinge in vitro migration and invasion suggested that it may drive tumorigenesis and metastatic progression in gastric cancer.
Having shown that miR-3978 suppressed tumor cell growth in MKN45 cells, we investigated its antitumor effects in a murine model of gastric cancer. Ectopic expression of miR-3978 in MKN45 cells ameliorated tumor growth as compared to mock transfected MKN45 cells (Figure 5A and 5B). When tissue samples obtained from each of 29 animals in this two experimental groups were assayed for legumain expression, we noticed a significantly higher legumain expression in animals that were not transfected with MKN45 cells (P<0.05) (Figure 5C). These data suggest that miR-3978 expression is inversely correlated to legumain expression and high expression of miR-3978 can potentially suppress gastric cancer formation and progression.
Figure 5: MiR-3978 expression levels dictate peritoneal metastasis of gastric cancer. A and B. The effect of miR-3978 overexpression on metastasis was examined. MKN45 cells stably overexpressing either scrambled control or mR-3978 mimic were used. The incidence of tumor formation and metastasis were measured by luciferin injection and bioluminescence imaging of Firefly Luciferase. C. Relative legumain protein expression as assessed by the percent score in the 29 animals in the two experimental groups.
Given that our experiments indicated that legumain is a bona-fide target of miR-3972, we hypothesized that suppression of miR-3978 expression might be an underlying feature of peritoneal metastasis pathogenesis in patients with gastric cancer. We determined miR-3978 and legumain protein expression in 20 gastric cancer patients with different stages of peritoneal metastasis. Our results indicated a dynamic and inverse correlation between down-regulation in the levels of miR-3978 and the observed increase in legumain protein expression in metastatic gastric cancer tissue specimens (Figure 6) (P < .005, Pearson correlation r = −0.8761).
Figure 6: MiR-3978 and legumain levels are inversely correlated in gastric cancer patients with metastatic disease. Pearson correlation demonstrating the inverse relation between miR-3978 (determined by qRT-PCR) and legumain (determined by immunohistochemistry) in paired samples (p < 0.05, Pearson correlation r = −0.8761).
In the current study, our experimental results show that miRNA-3978 and legumain is downregulated and upregulated, respectively, in gastric cancer patients with peritoneal metastasis. Repression of legumain expression by using miRNA-3978 mimic inhibited cell proliferation, as well as migration and invasion. Finally, modulating miR-3978 expression levels directly correlated to metastatic potential of the MKN45 cells in xenograft experiments. Cumulatively, this highlights loss of miR-3978 expression as potential prognostic biomarker in gastric cancer patients. It will be interesting to investigate in future research endeavors how miR-3978 and legumain expression varies and correlates to disease progression in patients that had either radiation therapy or adjuvant chemotherapy post-radical resection of the primary tumor. It would also be interesting to determine additional targets of miR-3978. To the best of our knowledge, putative targets of miR-3978 have not been defined until this study.
MiRNAs are evolutionarily conserved 21-23 nucleotides RNAs that regulate post-transcriptional gene expression either by blocking translation or degrading target messenger RNAs (mRNAs) [21, 22]. Given that our data showed that miR-3978 targeted LGMN transcript, but there was no overarching decrease in steady state expression of LGMN mRNA in patients with peritoneal metastasis, it can be envisioned that miR-3978 does not degrade LGMN transcript, but instead inhibits its translation. In fact, our in vitro reporter assays corroborate this hypothesis. It will be important in future to define the precise translational inhibition mechanism by which miR-3978 inhibits LGMN translation. MiRNAs can function in both normal and transformed cells, thus functioning as tumor suppressors or oncogenes, and have even been shown to play a role in metastasis [23–26].
Not much is known about role of miR-3978 in gastric cancer or in normal physiology. There has been one report that suggested differential expression of miR-3978 in lung cancer patients . Given that legumain is overexpressed in different tumors, it will be interesting whether loss of miR-3978 expression is a pervasive mechanism.
It will also be of potential interest to study how miR-3978 is regulated and what causes its suppression during metastatic progression of gastric cancer patients. Conversely, it will be important to verify if other known or predicted targets of miR-3978 are differentially expressed in gastric cancer patients with metastatic disease and whether they functionally contribute to the pathogenesis of peritoneal metastasis. Finally, peritoneal metastasis can happen as a result of colorectal or hepatic carcinoma too; hence, it will be imperative to correlate miR-3978 expression with stage of gastric and other cancers with potential of peritoneal metastasis. A complete understanding of miR-3978 mediated regulation of legumain might emerge from experiments looking at gene expression following overexpression and knockdown of miR-3978 in in vitro platforms
MATERIALS AND METHODS
Patients and tissue samples
The study protocol was approved by the Institutional Review Board of Sino-Japanese Friendship Hospital. A total of 20 patients (12 men and 8 women) who had surgery for gastric cancer between 2014 and 2015 at Sino-Japanese Friendship Hospital were included in this study after providing signed informed consent. The mean age of the patients was 61.34 years (range, 39-78 years). The inclusion criterion was presence of peritoneal metastasis at the time of initial presentation as confirmed by two independent pathologists. Paired tumor tissue and normal gastric tissue specimens were obtained from all patients included in the study.
MKN45 and HMrSV5 cell lines were purchased from the cell bank of Chinese Academy of Sciences. Cells were maintained in RPMI1640 medium (Life Technologies, Shanghai, China) supplemented with 20% FBS (Lonza, Germany). All cells were cultured in a 5% CO2 humidified atmosphere and at 37°C.
RNA, miRNA extraction and qRT-PCR
RNA isolation and qRT-PCR to query LGMN expression was done as described previously (12). MiRNA from cells and tissues were extracted by the mirVana miRNA isolation kit (Life Technologies, Shanghai, China) according to the manufacturer’s instructions. The expression levels of indicated miRNAs and RNU6B were detected by TaqMan miRNA assays (Life technologies, Shanghai, China). The -ΔΔCt method was used to analyze the data in each case and normalization was done to GAPDH and RNU6B expression for mRNA and miRNA, respectively.
Cloning, transfection, and luciferase assays
The LGMN 3' UTR clone in pMirTarget was obtained from Origene. The LGMN 3' UTR reporter was constructed by amplifying the endogenous LGMN 3' UTR from the Origene. XhoI and ApaI sites were added to the 5' and 3' ends of the fragment during the preceding PCR reaction and cloned into the XhoI and ApaI site on the Rr-luc-6XCXCR4 Renilla luciferase vector (Addgene). To make the LGMN 3’UTR mutant construct, site-directed mutagenesis was used to delete nucleotides 19-26 or 21-27, corresponding to the miR-6124 and miR-3978 binding sites, respectively. A firefly luciferase vector was used as transfection and normalization control in all luciferase assays. Constructs were sequence verified before being used in experiments. Indicated cells (4×104) were transiently transfected using Lipofectamine 3000 (Life Technologies, Shanghai, China) as per the manufacturer’s instructions. Where indicated, cells were transfected with miR-3978 or miR-6124 mimic or antagomir (Life Technologies, Shanghai, China) along with the LGMN 3’UTR reporters. Ninety-six hours after transfection, the renilla and firefly luciferase activities were measured consecutively using Dual-luciferase reporter assay system (Promega, Madison, Wisconsin, USA) as per manufacturer’s protocol. Each reporter plasmid was transfected at least twice in triplicate. Post-normalization the data was represented as relative fluorescence units (RFU) ± standard deviation (SD).
Cell proliferation assay
The MTT assay kit (Sigma-Aldrich, St. Louis, MO, USA) was used to measure cell proliferation rates. The relative optical density (OD), as mean ± standard deviation was calculated.
In vitro transwell migration and invasion assays
Culturex 96 well BME cell invasion and cell migration kits (R&D Systems, Marlborough, MA, US) were used to measure in vitro migration and invasion, respectively. Percent migration and invasion were calculated and expressed as mean ± standard deviation.
Six week-old male BALB/c nude mice under SPF conditions were obtained from Vital River Laboratories (Beijing, China) (approved by the Institutional Review Board of Sino-Japanese Friendship Hospital). The tumor model was done as described previously (20) using parental MKN45 cells or MKN45 cells expressing miR-3978 mimic (n=29 in each group). The cells were stably transfected with firefly luciferase before use in animal experiments to aid in in vivo luciferase imaging to detect progression of tumor formation and metastasis. Tissue microarrays (TMAs) were made from paired tumor and non-tumor tissue in each experimental group for comparison of legumain expression.
Immunohistochemistry was performed to determine legumain expression levels in patient samples as well as those obtained from the in vivo xenograft experiments. Tissue specimens were stained with anti-legumain antibody (Santa Cruz, 1:200 dilutions) and subsequently scored as described previously (12). Scoring was independently performed by two pathologists blinded to the identity of the tissue specimens.
All analyses were done by using the SPSS statistical software program version 18.0 (IBM Corporation, NY). Quantitative variables are presented as the mean ± standard deviation. Data analysis was performed using one-way ANOVA. Tukey's post-hoc test was used to determine the statistical significance in all pairwise comparisons of interest. Pearson correlation coefficients were computed to assess the association between ordinal miR-3978 and legumain. P<0.05 was considered to represent a statistically significant difference.
UTR: untranslated region; EMT: epithelial to mesenchymal transition; AEP: asparaginyl endopeptidase; miR-3978: microRNA-3978; LGMN: legumain; mRNAs: messenger RNAs
CONFLICTS OF INTEREST
The authors have no potential conflicts of interest.
This study was supported by Project of Jilin Provincial Development and Reform Commission (3J1122923429); Health Special Items of the Finance Department of Jilin Province (Sczsy201503).
Fu-Jian Ji and Xue-Dong Fang designed the experiments; Yi Zhang, Yuan-Yu Wu, Jun-Nan Jiang, and Xue-Song Liu carried out the experiments and participated in result interpretation; Yi Zhang wrote the manuscript; and all authors approved the manuscript.
1. Chen WQ, Zheng RS, Zhang SW, Zeng HM, Zuo TT, Jia MM, Xia CF, Zou XN, Hao J. Report of cancer incidence and mortality in China. 2012. China Cancer. 2015; 24: 1-10.
2. Cho JM, Jang YJ, Kim JH, Park SS, Park SH, Mok YJ. Pattern, Timing and Survival in Patients with Recurrent Gastric Cancer. Hepatogastroenterology. 2014; 61: 1148-53.
3. Tanaka T, Kumagai K, Shimizu K, Masuo K, Yamagata K. Peritoneal metastasis in gastric cancer with particular reference to lymphatic advancement; extranodal invasion is a significant risk factor for peritoneal metastasis. J Surg Oncol. 2000; 75: 165-71.
4. Boku T, Nakane Y, Minoura T, Takada H, Yamamura M, Hioki K, Yamamoto M. Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer. Br J Surg. 1990; 77: 436-9.
5. Hippo Y, Yashiro M, Ishii M, Taniguchi H, Tsutsumi S, Hirakawa K, Kodama T, Aburatani H. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res. 2001; 61: 889-95.
6. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000; 87: 236-42. doi: 10.1046/j.1365-2168.2000.01360.x.
7. Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, Swallow CJ. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol. 2001; 8: 50-9.
8. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature. 1980; 283: 139-46.
9. Barrett AJ, Rawlings ND, O'Brien EA. The MEROPS database as a protease information system. J Struct Biol. 2001; 134: 95-102. doi: 10.1006/jsbi.2000.4332.
10. Dando PM, Fortunato M, Smith L, Knight CG, McKendrick JE, Barrett AJ. Pig kidney legumain: an asparaginyl endopeptidase with restricted specificity. Biochem J. 1999; 339: 743-9.
11. Li N, Liu Q, Su Q, Wei C, Lan B, Wang J, Bao G, Yan F, Yu Y, Peng B, Qiu J, Yan X, Zhang S, et al. Effects of legumain as a potential prognostic factor on gastric cancers. Med Oncol. 2013; 30: 621. doi: 10.1007/s12032-013-0621-9.
12. Guo P, Zhu Z, Sun Z, Wang Z, Zheng X, Xu H. Expression of legumain correlates with prognosis and metastasis in gastric carcinoma. PLoS One. 2013; 8: e73090. doi: 10.1371/journal.pone.0073090.
13. Cui Y, Wang Y, Li H, Li Q, Yu Y, Xu X, Xu B, Liu T. Asparaginyl endopeptidase promotes the invasion and metastasis of gastric cancer through modulating epithelial-to-mesenchymal transition and analysis of their phosphorylation signaling pathways. Oncotarget. 2016; 7: 34356-70. doi: 10.18632/oncotarget.8879.
14. Liu C, Sun C, Huang H, Janda K, Edgington T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 2003; 63: 2957-64.
15. Lewen S, Zhou H, Hu HD, Cheng T, Markowitz D, Reisfeld RA, Xiang R, Luo Y. A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother. 2008; 57: 507-15. doi: 10.1007/s00262-007-0389-x.
16. Wang L, Chen S, Zhang M, Li N, Chen Y, Su W, Liu Y, Lu D, Li S, Yang Y, Li Z, Stupack D, Qu P, et al. Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer. J Cell Biochem. 2012; 113: 2679-86. doi: 10.1002/jcb.24143.
17. Zhen Y, Chunlei G, Wenzhi S, Shuangtao Z, Na L, Rongrong W, Xiaohe L, Haiying N, Dehong L, Shan J, Xiaoyue T, Rong X. Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis. Sci Rep. 2015; 5: 16599. doi: 10.1038/srep16599.
18. Bajjuri KM, Liu Y, Liu C, Sinha SC. The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity. ChemMedChem. 2011; 6: 54-9. doi: 10.1002/cmdc.201000478.
19. Murthy RV, Arbman G, Gao J, Roodman GD, Sun XF. Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res. 2005; 11: 2293-9. doi: 10.1158/1078-0432.ccr-04-1642.
20. Ishikawa M, Kitayama J, Yamauchi T, Kadowaki T, Maki T, Miyato H, Yamashita H, Nagawa H. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci. 2007; 98: 1120-7. doi: 10.1111/j.1349-7006.2007.00486.x.
21. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215-33. doi: 10.1016/j.cell.2009.01.002.
22. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6: 259-69. doi: 10.1038/nrc1840.
23. Aleckovic M, Kang Y. Regulation of cancer metastasis by cell-free miRNAs. Biochim Biophys Acta. 2015; 1855: 24-42. doi: 10.1016/j.bbcan.2014.10.005.
24. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel MA. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007; 67: 2456-68. doi: 10.1158/0008-5472.can-06-2698.
25. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007; 39: 673-7. doi: 10.1038/ng2003.
26. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-8. doi: 10.1038/nature03702.
27. Goto A, Dobashi Y, Tsubochi H, Maeda D, Ooi A. MicroRNAs associated with increased AKT gene number in human lung carcinoma. Hum Pathol. 2016; 56: 1-10. doi: 10.1016/j.humpath.2016.04.011.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.